2026 Interim Report
Filed with HKEX · Stock code 2157 · · 57 pages · English
Summary by 6ix AI
The report highlights a significant increase in revenue compared to the same period in the previous year, driven by strong sales of key oncology products. Additionally, the company discusses its ongoing clinical trials and advancements in its product pipeline, emphasizing its commitment to innovation in oncology therapeutics.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Lepu Biopharma Co. Ltd. on 6ix
Earlier from Lepu Biopharma
Later from Lepu Biopharma
- Voluntary announcement four clinical studies selected for presentation at 2026 ESMO congress: CMG901 (AZD0901) clinical trial results selected as LBA for proffered paper presentation at Presidential Symposium, MRG007 clinical trial results selected as LBA for rapid oral presentation, and two other studies selected for rapid oral presentation
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement CMG901 (AZD0901) clinical results presented as lba proffered paper at presidential symposium, MRG007 clinical results presented as lba, and encouraging data for MRG003 presented as rapid oral at esmo 2026
- Voluntary announcement increase in shareholding by the controlling shareholder
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
Follow Lepu Biopharma into a list and get an email when it puts out news.
Follow Lepu Biopharma